Regeneron

+$16.20 (+2.66%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Regeneron and other ETFs, options, and stocks.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.

CEO

Leonard S. Schleifer

Employees

9,123

Headquarters

Tarrytown, New York

Founded

1988

REGN Key Statistics

Market cap

Price-Earnings ratio

9.98

Dividend yield

—

Average volume

887.34K

High today

$625.00

Low today

$601.89

Open price

$608.29

Volume

736.05K

52 Week high

$686.62

52 Week low

$441.00

REGN News

Benzinga18h

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have voluntarily withdrawn their application with the FDA for the expanded

Reuters21h

UPDATE 1-Regeneron, Sanofi withdraw FDA application for cancer drug's expanded use

(Adds details on Libtayo sales) Jan 28 (Reuters) - Regeneron Pharmaceuticals Inc and its partner Sanofi voluntarily withdrew their application with the U.S. dr

MarketWatch21h

Regeneron, Sanofi withdraw application for Libtaya as a cervical cancer treatment in the U.S.

Shares of Regeneron Pharmaceuticals Inc. REGN, +0.57% were down 0.1% in premarket trading on Friday after the company and Sanofi SNY, +3.00% said they will no l

Analyst ratings

Buy

53.8%

Hold

42.3%

Sell

3.8%

REGN Earnings

$0.00

$8.60

$17.20

$25.80

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Estimated

$18.51 per share

Actual

Available Feb 4, Pre-Market

More REGN News

Reuters22h

Regeneron, Sanofi withdraw FDA application for Libtayo use in cervical cancer

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Br

AxiosJan 25

FDA limits use of Regeneron and Lilly COVID antibody treatments

The FDA said Monday it's limiting the use of two monoclonal antibody therapies as COVID-19 treatments because data indicates they're "highly unlikely" to be eff

The Wall Street JournalJan 24

Biden Administration Limits Use of Regeneron and Lilly Covid-19 Antibody Drugs

The Biden administration restricted the use of two monoclonal antibody drugs for Covid-19 because they are unlikely to be effective against the Omicron variant.

MarketWatchJan 24

FDA halts use of antibody drugs that don't work against omicron

WASHINGTON — COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don’t work against the omicron variant that now accounts

ReutersJan 24

U.S. FDA to restrict use of Regeneron, Lilly COVID antibody drugs - WaPo

Jan 24 (Reuters) - The U.S. Food and Drug Administration (FDA) is likely to restrict the use of COVID-19 antibody treatments from Regeneron and Eli Lilly as the

QuartzJan 22

Some US states still pushing ineffective covid antibody treatments

As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that fed